Vico Therapeutics B.V.

About Vico Therapeutics B.V.

Vico Therapeutics is a neurology genetic medicine company focused on developing targeted treatments for rare genetic neurological diseases. They specialize in antisense oligonucleotide (ASO) therapies to address the root causes of disorders like Huntington's disease and spinocerebellar ataxias (SCA), aiming to modify the disease's genetic source rather than just managing symptoms.

Products & Services

VO659:A clinical-stage candidate targeting the CAG repeat expansion mutation, the root cause of polyglutamine diseases, using an allele-preferential approach to reduce disease-causing mutations while preserving normal gene function.

Specialties

Antisense Oligonucleotide (ASO) Therapies Genetic Neurological Diseases Precision Genetic Targeting Polyglutamine Diseases Huntington's Disease Spinocerebellar Ataxias (SCA)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 60000000 MR: - FA: $60 million FAN: 60000000	D: 2024-01-05 FD: 2024-01-05	7 investors

Series B Latest

2024-01-05

$60.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Micah Mackison

Chief Executive Officer

LinkedIn (Pro only)

N

Nicole Datson

Chief Scientific Officer/Site Head

LinkedIn (Pro only)

S

Scott Schobel

Chief Medical Officer

LinkedIn (Pro only)

P

Prarthana Khanna

Vice President, Corporate Business Development and Strategy

L

Luc Dochez

Chair and Founder

M

Martijn Kleijwegt

View 10 more team members with Pro

Unlock Full Team Directory

Recent News